Tech Review

Permedicon – Unique European event for personalised medicine expands

13.04.2011

Cologne – Will personalised medicine become a reality? Is it economically feasible? Which regulatory requirements must be met to profit from new concepts for better defining and treating disease subpopulations? What criteria will health technology assessors adopt? On 21th-22th June, Cologne will become the temporary European capital of personalised medicine. All relevant stakeholders along the value chain – from biotech and pharma companies, CROs, hospitals, regulatory authorities, health technology assessors, patient organisations, and research institutions – will meet up at PerMediCon to discuss current trends, challenges and opportunities in the emerging field of personalised medicine.“Our meeting is the only event in Europe devoted exclusively to personalised medicine,” says Dr. Christian Glasmacher, Vice President from organiser Koeln­messe. “It gathers together the entire spectrum of key players and stakeholders from the different worlds – from development, manufacure, use, authorisation and marketing of personalised medicines – in one place.” At its kick-off last year, PerMediCon attracted 300 visitors and 20 exhibitors. This year, Glasmacher expects 50 exhibitors and 500 experts to attend. The two-day event is a unique mixture of congress (with top lecturers), exhibition and truly interdisciplinary discussion forums on hot topics and pressing questions in the sector.

Meeting point for key players

The Personalized Medicines Convention (www.permedicon.com) gives an update on the perspectives of the very different stakeholders involved. Koelnmesse has invented its own format to bring the key players into discussion. Afternoons at the two-day event have been reserved for 12 interactive dicussions on current topics in “R&D innovations”, “Applications” and “General issues” (the economics of personalised medicine, requirements for the design of clinical studies, biobanking, and others). The focussed workshops start with a ten-minute lecture on the topic. This is followed by a discussion round with five experts (40 mins) and general discussion (15 mins), and ends with a summary of results. “The event aims to bring all stakeholders together in a Euro­pean format,” says Glasmacher. A similar process has already occurred in the US – and keynote lecturer Edward Abrahams will be in Cologne to talk about it.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/permedicon-unique-european-event-for-personalised-medicine-expands.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK70.9%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.1%
  • IMMUNICUM AB (S)16.60 SEK-38.1%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP750.0%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-96.0%
  • EVOCUTIS (UK)0.22 GBP-92.3%
  • AGENNIX (D)0.04 EUR-80.0%

No liability assumed, Date: 22.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper